|
Variable
|
Pyridostigmine (n = 127)
|
Sugammadex (n = 127)
|
p value
|
|---|
|
Age (year)
|
66.0 (59.5–71.0)
|
67.0 (60.0–72.0)
|
0.358
|
|
Male sex
|
92 (72.4)
|
96 (75.6)
|
0.668
|
|
Height (cm)
|
163.0 (159.0–168.5)
|
163.0 (158.0–168.0)
|
0.640
|
|
Weight (kg)
|
62.0 (56.0–67.0)
|
61.0 (56.0–69.5)
|
0.817
|
|
BMI (kg m−2)
|
23.1 (21.5–25.5)
|
23.5 (21.3–25.7)
|
0.445
|
|
ASA PS
| | |
0.238
|
|
I
|
14 (11.0)
|
19 (15.0)
| |
|
II
|
104 (81.9)
|
93 (73.2)
| |
|
III
|
9 (7.1)
|
15 (11.8)
| |
|
Diabetes mellitus
|
22 (17.3)
|
27 (21.3)
|
0.525
|
|
Hypertension
|
55 (43.3)
|
55 (43.3)
|
1.000
|
|
CKD
|
5 (3.9)
|
2 (1.6)
|
0.443
|
|
Heart failure
|
3 (2.4)
|
0 (0.0)
|
0.245
|
|
CAD
|
14 (11.0)
|
12 (9.4)
|
0.836
|
|
COPD
|
28 (22.0)
|
31 (24.4)
|
0.766
|
|
Asthma
|
3 (2.4)
|
0 (0.0)
|
0.245
|
|
Operation site (right)
|
85 (66.9)
|
76 (59.8)
|
0.297
|
- Data are presented as n (%), median (interquartile range)
- BMI Body mass index, ASA PS American Society of Anesthesiologists physical status, CKD Chronic kidney disease, CAD Coronary arterial disease, COPD Chronic obstructive pulmonary disease
